Recombinant coagulation factor

This page covers all Recombinant coagulation factor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tissue factor (TF) / Factor X, Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site, Coagulation Factor IX (FIX).

Targets

Tissue factor (TF) / Factor X · Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site · Coagulation Factor IX (FIX) · Fibrinogen (Factor I) · Tissue factor (TF); Factor X

Marketed (4)

• Eptacog alfa (NovoSeven) · Novo Nordisk A/S · Hematology
  Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.
• Recombinant Von Willebrand factor · Nicoletta C Machin · Hematology
  Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding.
• RIXUBIS: Prophylaxis · Baxalta now part of Shire · Hematology
  Rixubis is a recombinant Factor IX (prothrombin complex component) that replaces deficient clotting factor to restore the intrinsic coagulation pathway.
• RIXUBIS: On-Demand · Baxalta now part of Shire · Hematology
  RIXUBIS is a recombinant Factor IX that replaces deficient or dysfunctional clotting factor IX to restore blood coagulation in patients with hemophilia B.

Phase 3 pipeline (2)

• rThrombin · ZymoGenetics · Hematology
  rThrombin is a recombinant human thrombin that directly converts fibrinogen to fibrin to promote blood clotting and hemostasis.
• Eptacog alfa, biosimilar · AryoGen Pharmed Co. · Hematology
  Eptacog alfa is a recombinant activated Factor VII that bypasses upstream coagulation defects to directly activate Factor X and initiate thrombin generation for hemostasis.